it has acquired a royalty interest in worldwide sales of Xenpozyme for US$30-million. The company said additional performance-based milestones of up to US$26.5-million could be paid if sales of the drug outperform expectations.
The company said Xenpozyme is the only product developed and approved for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency , also known as Niemann-Pick disease. “Xenpozyme is a product that provides ASMD patients and their families with a disease-modifying therapy where none previously existed. The drug represents a transformational shift in therapies available to patients who suffer from ASMD,” said CEO Behzad Khosrowshahi.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Five things to watch for in the Canadian business world in the coming weekTORONTO - Five things to watch for in the Canadian business world in the coming week:
Source: TorontoStar - 🏆 60. / 55 Read more »